Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Public ClinicalTrials.gov record NCT05462717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Study identification
- NCT ID
- NCT05462717
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Enrollment
- 222 participants
Conditions and interventions
Conditions
Interventions
- RMC-6291 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 18, 2022
- Primary completion
- Mar 30, 2027
- Completion
- Sep 29, 2027
- Last update posted
- Apr 7, 2026
2022 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| UC Irvine Cancer Center | Orange | California | 92868 | — |
| UC Davis Cancer Center | Sacramento | California | 95817 | — |
| UCSF | San Francisco | California | 94158 | — |
| University of Miami School of Medicine Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| American Oncology Partners of Maryland | Bethesda | Maryland | 20817 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14203 | — |
| MSK Cancer Center | New York | New York | 10021 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Next Oncology | San Antonio | Texas | 78229 | — |
| START | San Antonio | Texas | 78229 | — |
| Next Oncology Virginia | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05462717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 7, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05462717 live on ClinicalTrials.gov.